CANN AMERICAN CORP. Inactive Instrument
Cann American Corp. Share Price Other OTC
Equities
CNNA
US13764N2071
Pharmaceuticals
| Sales 2022 | - | Sales 2023 | - | Capitalization | 964K 80.05M |
|---|---|---|---|---|---|
| Net income 2022 | 10M 830M | Net income 2023 | 3M 249M | EV / Sales 2022 | - |
| Net Debt 2022 | 202K 16.76M | Net Debt 2023 | 311K 25.83M | EV / Sales 2023 | - |
| P/E ratio 2022 |
0.12
x | P/E ratio 2023 |
0.19
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Jason Tucker
CEO | Chief Executive Officer | - | 01/23/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jason Tucker
CEO | Chief Executive Officer | - | 01/23/01 |
Pete Caruso
BRD | Director/Board Member | - | 01/23/01 |
Michael Kramer
BRD | Director/Board Member | - | 10/23/10 |
Cann American Corp. is a holding company. The Company is engaged in developing assets within the legal cannabis and hemp industries. The Company has two subsidiaries, Cannequipt, LLC and Hourglass Enterprises LLC. Cannequipt, LLC, intends to act as a research and development division. Hourglass Enterprises LLC, intends to focus on developing new assets in the state of Oklahoma. The Company primarily within the state of California.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +38.51% | 727B | |
| +33.05% | 599B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +16.00% | 243B | |
| +8.09% | 205B | |
| -5.77% | 203B | |
| +6.19% | 164B |
